Clinical trials: Hepatic
Hepatocellular Carcinoma, Laser Ablation
Laser Ablation for Intermediate and Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Hepatocellular carcinoma (HCC) is the fifth most-common cancer worldwide and the second most-common cause of cancer mortality. Liver resection is the first-line curative treatment for huge HCC.
- Conditions
- Hepatocellular Carcinoma, Laser Ablation, Portal Vein Tumor Thrombus
- Trial name
- NCT02724475
- Testing
- LA, 3D-CRT
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Acute Kidney Injury, Hyperglycemia
Impact of Glycemic Control After Reperfusion on Acute Kidney Injury in Living Donor Liver Transplantation
This retrospective cohort study of patients classified by the blood glucose level after reperfusion in liver transplantation repicient.
- Conditions
- Acute Kidney Injury, Hyperglycemia, Hypoglycemia, End Stage Liver Disease
- Trial name
- NCT06320730
- Testing
- Observational study, records of blood glucose level after reperfusion
- Where
- South Korea
- Volunteers
- 3,790 people
- Sponsor
- Asan Medical Center
Chronic Hepatitis C, Cirrhosis
Transient Elastography to Assess Liver Fibrosis and Portal Hypertension in HCV Cirrhotic Patients Treated With New Antiviral Drugs (SPLEEN-C)
The purpose of this study is to evaluate the effects of sustained virological response in liver and spleen stiffness in patients with HCV compensated advanced chronic liver disease treated with new all oral antiviral drugs in…
- Conditions
- Chronic Hepatitis C, Cirrhosis, Portal Hypertension
- Trial name
- SPLEEN-C (NCT02439567)
- Testing
- Fibroscan: Liver and Spleen elastography
- Where
- Spain
- Volunteers
- 41 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Hepatic Insufficiency, Healthy
A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
The main purpose of this study is to measure how much of Imlunestrant (LY3484356) gets into the bloodstream and how long it takes the body to eliminate it in female participants with impaired liver function compared to female…
- Trial name
- NCT05440344
- Testing
- Imlunestrant
- Where
- 3 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hepatitis B
Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation
This is a phase IIIb comparative study of entecavir 1.0 mg once daily (QD) vs. adefovir 10 mg QD in patients who have chronic hepatitis B infection and hepatic decompensation.
- Trial name
- NCT00065507
- Testing
- Entecavir (ETV), Adefovir (ADV)
- Where
- 61 sites in United States, Brazil and 15 more
- Volunteers
- 195 people
- Sponsor
- Bristol-Myers Squibb
Porphyria, Acute Intermittent
Clinical Research on Acute Intermittent Porphyria and the Use of Carbohydrate-Rich Diet as a Treatment
The main aim of this clinical trial is to learn about the effect of carbohydrate-rich diet as a treatment for AIP (acute intermittent porphyria).
- Trial name
- NCT06273644
- Testing
- Carbohydrates
- Where
- 3 sites in Norway, Sweden
- Volunteers
- 50 people
- Sponsor
- Nordlandssykehuset HF
Urea Cycle Disorder, Crigler-Najjar Syndrome
HepaStem Long-Term Safety Registry
All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Biosciences
- Conditions
- Urea Cycle Disorder, Crigler-Najjar Syndrome, Acute on Chronic Liver Failure
- Trial name
- PROLONGSTEM (NCT03343756)
- Where
- 29 sites in Belgium, Bulgaria and 3 more
- Volunteers
- 44 people
- Sponsor
- Cellaion SA
Hepatic Impairment
Pharmacokinetics of BAF312 in Patients With Hepatic Impairment
This study will investigate the pharmacokinetics of BAF312 in patients with mild, moderate and severe hepatic impairment compared to healthy control subjects.
- Trial name
- NCT01565902
- Testing
- BAF312
- Where
- 3 sites in Hungary, Russia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Ulcerative Colitis (UC), Steatotic Liver Disease
Ulcerative Colitis Permeability
Study aim: To investigate whether the values of zonulin and lipopolysaccharide-binding protein (LBP) as biomarkers of intestinal permeability are related to the degree of liver steatosis, steatohepatitis and fibrosis in patients…
- Conditions
- Ulcerative Colitis (UC), Steatotic Liver Disease, Intestinal Permeability
- Trial name
- UCP (NCT07662902)
- Where
- Croatia
- Volunteers
- 100 people
- Sponsor
- University Hospital Dubrava
Type 2 Diabetes Nonalcoholic Fatty Liver
The Effects of Coffee Main Constituents (Caffeine and Chlorogenic Acid) Supplementation on Inflammatory, Metabolic Factors, Hepatic Steatosis and Fibrosis in None- Alcoholic Fatty Liver Patients With Type 2 Diabetes
The purpose of this study is to investigate the effects of coffee main constituents (caffeine and chlorogenic acid) supplements on inflammatory, metabolic factors, hepatic steatosis and fibrosis in none- alcoholic fatty liver…
- Trial name
- NCT02929901
- Testing
- caffeine and chlorogenic acid, caffeine, chlorogenic acid
- Where
- Iran
- Volunteers
- 200 people
- Sponsor
- National Nutrition and Food Technology Institute
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease
Impact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is one of the most common chronic liver conditions globally.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hypothyroidism, Liver Fibrosis
- Trial name
- NCT07827430
- Volunteers
- 120 people
- Sponsor
- Assiut University
Achalasia, Esophageal
Metabolic Changes Associated With Weight Gain After Treatment of Achalasia
This goal of the study is to assess the effect of weight gain in patients with achalasia after they are treated. The main question to be answered is if weight gain after achalasia treatment is associated with worsening metabolic…
- Trial name
- NCT07334639
- Where
- 2 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Assaf-Harofeh Medical Center
Advanced Adult Primary Liver Cancer, Liver Metastases
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
This pilot clinical trial studies positron emission tomography (PET)/computed tomography (CT) in finding beads after Yttrium-90 bead therapy in patients with primary liver cancer or cancer that has spread to the liver…
- Conditions
- Advanced Adult Primary Liver Cancer, Liver Metastases, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT02119065
- Testing
- positron emission tomography, computed tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Cincinnati
Liver Cirrhosis, Portal Vein Thrombosis
Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis
Several studies have confirmed that patients with cirrhosis possess an imbalance in procoagulant versus anticoagulant activity due to increased factor VIII and decreased protein C.
- Trial name
- NCT02069457
- Where
- China
- Volunteers
- 151 people
- Sponsor
- Jia Ji-Dong
Hepatic Cirrhosis
Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites
Multicentric, observational and prospective study with two groups of treatment: Refractory ascites and non-refractory ascites. All patients should be prescribed beta-adrenergic blockers as primary or secondary profilaxis for…
- Trial name
- ALB-BET (NCT02163512)
- Where
- 2 sites in Spain
- Volunteers
- 46 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Biliary Tract Cancer
HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
This is a single-arm, exploratory, phase II trial to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy combined with adebrelimab and lenvatinib for borderline resectable, locally advanced biliary tract…
- Trial name
- NCT06389500
- Testing
- Adebrelimab, Lenvatinib, Hepatic Arterial Infusion Chemotherapy
- Volunteers
- 30 people
- Sponsor
- Harbin Medical University
Hepatic Encephalopathy
Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy
The aim of this study is to evaluate the efficacy of lactoferrin as an adjunct therapy in improving clinical symptoms and laboratory indices in individuals with hepatic encephalopathy.
- Trial name
- NCT06072521
- Testing
- Lactoferrin Bovine
- Where
- Egypt
- Volunteers
- 45 people
- Sponsor
- Al-Azhar University
Cirrhosis Portal
Portal Vein Flow Velocity as a Screening Tool for Oesophageal Varices in Cirrhotic Patients
Portal vein flow velocity as screening tool for prediction of oesophageal varices in cirrhotic patient without upper endoscopy
- Trial name
- Portalflow (NCT05228509)
- Where
- 2 sites in Egypt
- Volunteers
- 75 people
- Sponsor
- Peter atef
Severe Hepatic Impairment
Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects
The primary objective of this study is to characterize the steady state plasma
- Trial name
- NCT03818672
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Cirrhosis, Liver, Portal Hypertension
Carvedilol for Prevention of Esophageal Varices Progression
Carvedilol has been shown to be more potent in decreasing portal hypertension to propranolol. But the efficacy of carvedilol to delay the growth of esophageal varices in chronic hepatitis B patients was unclear.
- Trial name
- Carvedilol (NCT03736265)
- Testing
- Carvedilol
- Where
- 6 sites in China
- Volunteers
- 240 people
- Sponsor
- Beijing Friendship Hospital